ClinicalTrials.gg
RecruitingNCT07537738MLL-LSCUpdated Apr 17, 2026

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

An observational study in Acute Myeloid Leukemia (AML) and MLL Rearrangement, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
210
Ages
6 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.

Started
2025
with 1 other
Observational
3 of 20
3 open now
Primary completion
2026-04
later than 4 of 15 live
Registered
18th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is one of 2 that started in 2025, is one of 3 observational ones, reaches primary completion later than 4 of the 15 other live ones, and was the 18th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 6 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:

  • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • MLL Rearrangement

Keywords

  • acute myeloid leukemia
  • leukemia stem cell
  • allo-SCT
04

Who can participate

Ages eligible
6 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.

Exclusion criteria

Exclusion Criteria:

  1. Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation.
  2. Patients who cannot comply with the study.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • AML patients with MLL rearrangement

    AML patients with MLL rearrangement who recieved chemnoptherapy or unerwent allo-SCT

    Diagnostic Test: Detection of leukemia stem cell using multiparameter flow cytometry

Interventions

  • Diagnostic testDetection of leukemia stem cell using multiparameter flow cytometry

    For AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.

06

What researchers measure

Primary outcomes

  1. Relapse

    Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites

    Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.

Secondary outcomes

  1. leukemia-free survival

    Leukemia-free survival was defined as survival in continuous complete remission.

    Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.

  2. overall survival

    Overall survival referred to patients who survived until the final follow-up time point

    Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Lowenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ. CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 2019 May;33(5):1102-1112. doi: 10.1038/s41375-018-0326-3. Epub 2018 Dec 12. PubMed 30542144 ↗
  • Li SQ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Lv M, Tang FF, Mo XD, Liu KY, Huang XJ, Chang YJ. Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study. Bone Marrow Transplant. 2025 Nov;60(11):1472-1479. doi: 10.1038/s41409-025-02699-8. Epub 2025 Aug 23. PubMed 40849363 ↗
  • Li SQ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Lv M, Tang FF, Mo XD, Liu YR, Liu KY, Chang YJ, Huang XJ. An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood. 2022 Aug 4;140(5):516-520. doi: 10.1182/blood.2021014604. No abstract available. PubMed 35613411 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 17, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Apr 7, 2026
CompletionEst.
Apr 7, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07537738
Responsible party
Siqi Li (Chief Technician, Peking University People's Hospital) — Principal investigator
First posted
Apr 17, 2026
Start date
Jun 1, 2025
Primary completion
Apr 7, 2026 (estimated)
Completion
Apr 7, 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

Siqi Li, PhD
Contact
tina_li_1995@163.com
+86 18611944638

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion